Coronary Artery Disease Therapeutics Market Positive Long-Term Growth Outlook 2018-2026

Coronary Artery Disease Therapeutics Market Will
Witness a Staggering Growth During 2018-2026
Coronary Artery Disease Therapeutics Market, by Drug Type (Beta Blockers,
Calcium Channel Blockers, ACE Inhibitors, Nitrates, Statin, and Others), by End
User, and by Region (North America, Europe, Latin America, Asia Pacific, Middle
East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Coherent Market Insights added Latest Research Report titled " Coronary Artery Disease
Therapeutics Market, by Drug Type (Beta Blockers, Calcium Channel Blockers, ACE Inhibitors,
Nitrates, Statin, and Others), by End User, and by Region (North America, Europe, Latin America, Asia
Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026 " to its Large Report database.
Coronary Artery Disease (CAD) is a medical condition developed due to damaged or diseased blood
vessels, which supply blood, nutrients, and oxygen to the heart. Coronary heart disease is characterized
by deposition of cholesterol plague in the arteries, which results into inflammation. Increasing
deposition of plague eventually narrows the coronary arteries thereby decreasing the blood flow to the
heart. Decrease of blood flow to the heart causes shortness of breath and chest pain leading to heart
attack after complete blockage.
Coronary artery disease is caused by smoking, high blood pressure, high cholesterol, diabetes or insulin
resistance, sedentary lifestyle, and hypertension. Other factors involved in developing coronary artery
disease include obesity, physical inactivity, high stress, and unhealthy diet. Coronary artery disease can
be prevented by maintaining healthy diet, consumption of low fat and low salt fruits and vegetables,
physical activity, and management of stress. Treatment of coronary artery disease includes cholesterol
modifying medications, ACE inhibitors, Aspirin, beta blockers, Calcium channel blockers, and
Ranolazine. Surgeries conducted to treat coronary artery disease include Nitroglycerin, Angioplasty,
and coronary artery bypass surgery.
Coronary Artery Disease Therapeutics Market Drivers:The global market is expected to witness significant growth due to robust pipeline of drugs over the
forecast period (2018-2026). For instance, hydroxychloroquine sulfate tablets sponsored by first
affiliated hospital of Xi’an Jiaotong university, China is in the fourth phase of clinical trials, this drug
suppresses symptoms of coronary artery disease. Atorvastatin sponsored by university health network,
Toronto has completed phase two clinical trials in 2014, this drug reduces the risk of heart attack and
myocardial infraction. PADMA 28 sponsored by University hospital Inselsiptal, Berne has completed
phase 2 clinical trials in 2013, this drug has beneficial effect on arterial system, the autonomic nervous
system and blood inflammatory markers in patients with coronary artery disease.
Furthermore, approval of new drugs for coronary artery disease is another factor driving growth of the
coronary artery disease therapeutics market. For instance, in 2016, the U.S. FDA approved Yosprala
(Aspirin and Omeprazole) by Aralez Pharmaceuticals, a Canada-based company, this drug is used to
prevent cardiovascular diseases. In 2015, FDA approved Repatha by Amgen Inc. This drug is used to
treat high cholesterol. In 2015, FDA approved Prestalia by Symplmed Pharmaceuticals LLC, this drug
is used to treat hypertension for people suffering with heart disorders. Later in 2017, Prestalia was
acquired by Marina Biotech Inc.
Coronary Artery Disease Therapeutics Market Taxonomy:The global market is segmented based on drug type, distribution channel and region.
By Drug Type:•Beta Blockers
•Calcium Channel Blockers
•ACE Inhibitors
•Nitrates
•Statin
•Others
By Distribution Channel:•Hospitals
•Online Pharmacies
•Retail Pharmacies
Key Players
Key players operating in coronary artery disease therapeutics market include Astra Zeneca, Gilead,
Novartis, Pfizer, Bayer, Merck & Co, Glaxo Smith Kline, and Mylan N.V.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1799
Coronary Artery Disease Therapeutics Market Regional Analysis:North America is expected to hold dominant position in global coronary artery disease therapeutics
market due to high prevalence of coronary artery disease. According to a survey conducted by Centers
for disease control and prevention (CDC), in 2015, coronary heart disease kills more than 370,000
people annually in the U.S. out of which more than 92% had chest pain as a major symptom. According
to a study conducted by American College of Cardiology, in 2017, more than 790000 people
experience heart attack annually in the U.S. out of this around 47% people were reported to have
hypertension and around 34% were reported to have high blood pressure.
Therefore, high prevalence of chronic diseases are expected to drive growth of this market over the
forecast period. Asia Pacific coronary artery disease therapeutics market is projected to witness
significant growth due to FDA approvals for generic drugs. For instance, in 2017, Lupin, India-based
Company received FDA approval to launch generic version of Nadolol Tablets, indicated for the
treatment of hypertension and angina pectoris.
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: sales@coherentmarketinsights.com

Coherent Market Insights added Latest Research Report titled " Coronary Artery Disease Therapeutics Market, by Drug Type (Beta Blockers, Calcium Channel Blockers, ACE Inhibitors, Nitrates, Statin, and Others), by End User, and by Region (North America, Europe, Latin America, Asia Pacific, Middle East, and Africa) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2018-2026 " to its Large Report database.